•aˆö•a‘ÔˆãŠwuÀ^”÷¶•¨Šw—̈æ

 

1D    —̈æ\¬‹³EˆõEÝEŠúŠÔ

‹³Žö

’è@´’¼

•½¬‚P‚W”N‚P‚OŒŽ 〜

‹³Žö

–Ø‘º@‹g‰„

º˜a‚T‚U”N‚SŒŽ 〜 •½¬‚P‚W”N‚RŒŽ

•‹³Žö

Œã“¡@•q

•½¬@‚U”N‚SŒŽ 〜 •½¬‚P‚W”N‚RŒŽ

•Žè

¬¼@Fs

•½¬Œ³”N‚P‚OŒŽ 〜

•Žè

’|“à@Œ’Ži

•½¬@‚R”N‚SŒŽ 〜

 

 

 

2D    Œ¤‹†ŠT—v

ƒAƒ_ƒvƒ^[’`”’Ž¿3BP2‚̶—“IE•a—“I–ðŠ„A‚¨‚æ‚ÑHCVŠ´õ‚̃VƒOƒiƒ‹“`’B‹@\‚ɂ‚¢‚Ă̌¤‹†

 

œ  Œ¤‹†ŠT—v

“–—̈æ‚Å‚Í2006”N3ŒŽ‚É–Ø‘º‹g‰„‹³Žö‚ƌ㓡•q•‹³Žö‚ª‘ÞŠ¯‚µA“¯”N10ŒŽ‚ɒ肪Œã”C‹³Žö‚Æ‚µ‚Ä_ŒË‘åŠw‚æ‚è’…”C‚µV‚µ‚¢ƒXƒ^[ƒg‚ðØ‚Á‚½B2007”N2ŒŽ‚ɂ͉HŸâ•Žè‚ªV‚½‚ɉÁ‚í‚é—\’è‚Å‚ ‚éB

“–Œ¤‹†Žº‚ÌŽå—v‚ÈŒ¤‹†ƒe[ƒ}‚ÍA×–E“àƒVƒOƒiƒ‹“`’BA“Á‚ɃAƒ_ƒvƒ^[’`”’Ž¿‚ÉŠÖ‚·‚é‚à‚̂ł ‚éB

1.
ƒAƒ_ƒvƒ^[’`”’Ž¿3BP2‚̶—“IE•a—“I–ðŠ„‚É‚Â‚¢‚Ă̌¤‹†@
ƒVƒOƒiƒ‹“`’B•ªŽq‚ÍA¶‘̂̈ێ‚⬒·‚É•s‰ÂŒ‡‚È”½‰ž‚ÉŠÖ‚í‚èA“Á’è‚©‚Âd—v‚È–ðŠ„‚ð’S‚Á‚Ä‚¢‚éBƒVƒOƒiƒ‹“`’B•ªŽq‚̈êŽí‚Å‚ ‚éƒAƒ_ƒvƒ^[’`”’Ž¿‚Í‘¼‚Ì•ªŽq‚Ɖ·‚邽‚߂̋@”\ƒhƒƒCƒ“‚ð—L‚·‚邪AŽ©‚ç‚Íy‘fŠˆ«‚ðŽ‚½‚È‚¢‚½‚ßA’P‚È‚éuŒq‚¬–ðv‚Ì•ªŽq‚Æ‚³‚ꂱ‚ê‚܂ł ‚Ü‚èd—vŽ‹‚³‚ê‚È‚©‚Á‚½B‚í‚ê‚í‚ê‚̓Aƒ_ƒvƒ^[’`”’Ž¿3BP2‚ª‚æ‚èϋɓI‚ɃVƒOƒiƒ‹“`’B‚ð’²ß‚µA×–E‰ž“š‚ɉe‹¿‚ð—^‚¦‚Ä‚¢‚邱‚Ƃ𖾂炩‚É‚µ‚Ä‚«‚½BƒAƒ_ƒvƒ^[’`”’Ž¿3BP2ˆâ“`Žq‚Ì“_“Ë‘R•ψق̓qƒgˆâ“`޾г‚̃Pƒ‹ƒrƒYƒ€Ç‚ðˆø‚«‹N‚±‚·‚±‚Æ‚ª•ñ‚³‚êA‚Ü‚½‰ºŠ{œ‚Ì”­’B•s‘S‚Ƹ_’x‘؂𔺂¤Wolf-HirschhornÇŒóŒQ‚âäNã÷Šà‚É‚¨‚¢‚Ä‚à3BP2ˆâ“`Žq‚ªŒ‡Ž¸‚·‚éB‚í‚ê‚í‚ê‚ÍAŠù‚ɃPƒ‹ƒrƒYƒ€Œ^‚Ì3BP2‚ª‹@”\•s‘SŒ^‚ðŽ¦‚·‚±‚ƂȂNj»–¡[‚¢’mŒ©‚ð•ñ‚µ‚Ä‚¢‚éB¡Œã‚ÍAƒAƒ_ƒvƒ^[’`”’Ž¿3BP2‚̕ψقɂæ‚éƒPƒ‹ƒrƒYƒ€Ç‚Ì”­Ç‚Æ•a‘Ԃɂ‚¢‚Ă̜–ƉuŠw“I‰ðÍ‚âA3BP2‚Æ•¡‡‘Ì‚ðŒ`¬‚·‚éŽó—e‘Ì’`”’Ž¿‚ɂ‚¢‚Ă̋@”\‰ðÍ‚ði‚߂Ă¢‚«‚½‚¢‚Æl‚¦‚Ä‚¢‚éB

2. C
Œ^ŠÌ‰ŠƒEƒCƒ‹ƒXŠ´õ‚É‚æ‚éƒVƒOƒiƒ‹“`’B‹@\‚ɂ‚¢‚Ă̌¤‹†
C
Œ^ŠÌ‰ŠƒEƒCƒ‹ƒXiHCVj‚ÍŠÌ‘Ÿ‚É–«‚̉ŠÇ‚ð‹N‚±‚µ‚—¦‚ÉŠÌ×–EŠà‚ðˆø‚«‹N‚±‚·‚ªA‚»‚Ì•ªŽq‹@˜‚ɂ‚¢‚Ă͕s–¾‚Ì“_‚ª‘½‚¢BŒ»ÝAHCVŠ´õ‚É‚æ‚éhŽå’`”’Ž¿‚Ì”­Œ»‚Æ‹@”\A“Á‚É×–E“àƒVƒOƒiƒ‹“`’B‹@\‚ւ̉e‹¿‚ɂ‚¢‚Ä–Ô—…“I‚ɉðÍ‚ði‚߂Ă¢‚éB

‚»‚Ì‘¼A–Ø‘º‘O‹³Žö‚ÌRSƒEƒCƒ‹ƒXŠ´õ‚É‚æ‚é¶‘Ì–hŒä‹@\‚ÌŒ¤‹†‚âAŒã“¡•‹³Žö‚̃pƒ‰ƒ~ƒNƒ\ƒEƒCƒ‹ƒX‚É‚æ‚éƒCƒ“ƒ^[ƒtƒFƒƒ“’ïR«‚ÌŒ¤‹†‚ªˆê•”Œp‘±‚µ‚Äs‚í‚ꂽB‚Ü‚½–ƉuŠwEŠñ¶’ŽŠw‚̈ɕەŽè‚Ƃ̋¤“¯Œ¤‹†‚ªs‚í‚ꂽB

 

œ  ƒL[ƒ[ƒh

¶‰»Šwˆê”Ê, ƒEƒCƒ‹ƒXŠw, ¶‘Ì–hŒä‚ƖƉuŒnˆê”Ê, ×–E“àƒVƒOƒiƒ‹“`’B, ƒAƒ_ƒvƒ^[’`”’Ž¿, ‚bŒ^ŠÌ‰ŠƒEƒCƒ‹ƒX, ƒCƒ“ƒ^[ƒtƒFƒƒ“, ƒAƒŒƒ‹ƒM[

 

œ  ‹ÆÑ”N‚Ìi’»ó‹µ

1. ƒAƒ_ƒvƒ^[’`”’Ž¿3BP2‚̶—“IE•a—“I–ðŠ„‚É‚Â‚¢‚Ă̌¤‹†@
3BP2
‚ð‰î‚·‚é¶—ì—p‚Æ•a—ì—p‚̉ð͂Ɋւ·‚霖ƉuŒn‚ÌV‹KŽÀŒ±Œn‚Ì—§‚¿ã‚°‚ðs‚Á‚½B‚í‚ê‚í‚ê‚̓Aƒ_ƒvƒ^[’`”’Ž¿‚ɂ‚¢‚Ă̌¤‹†‚̈ꕪ–ì‚Æ‚µ‚ÄAƒAƒ_ƒvƒ^[—l‹@”\‚ð—L‚·‚é’`”’Ž¿ƒ†ƒrƒLƒ`ƒ“ƒŠƒK[ƒ[A“Á‚ÉCbl‚ɂ‚¢‚Ă̌¤‹†‚ÉŽæ‚è‘g‚ñ‚Å‚¨‚èA–{”N‚Í—‰»ŠwŒ¤‹†Š‚Æ“Œ‹ž–ò‰È‘åŠw‚Ƃ̋¤“¯Œ¤‹†‚É‚æ‚èAƒ~ƒgƒRƒ“ƒhƒŠƒA‚É”­Œ»‚·‚éV‹Kƒ†ƒrƒLƒ`ƒ“ƒŠƒK[ƒ[‚𓯒肵Aƒ~ƒgƒRƒ“ƒhƒŠƒA‹@”\‚ð§Œä‚·‚邱‚Æ‚ð•ñ‚µ‚½B

2. C
Œ^ŠÌ‰ŠƒEƒCƒ‹ƒXŠ´õ‚É‚æ‚éƒVƒOƒiƒ‹“`’B‹@\‚ɂ‚¢‚Ă̌¤‹†
HCV
ƒQƒmƒ€—R—ˆ‚Ì’`”’Ž¿‚Í‘½Ê‚È•a—ì—p‚ð—L‚·‚éB–{”N‚ÍAHCVƒEƒCƒ‹ƒX’`”’Ž¿NS3ANS4A‚É‚æ‚éhŽå’`”’Ž¿‚Æ‚Ì‰ï‡‚ÆŠà”­Ç‹@\‚ւ̉e‹¿‚ɂ‚¢‚ĉðÍ‚ðs‚¢ANS3‚ÆŠà—}§ˆâ“`ŽqŽY•¨p53‚Ƃ̉̕ªŽqƒƒJƒjƒYƒ€‚Æ—}§‹@˜‚âANS4A‚É‚æ‚éƒ~ƒgƒRƒ“ƒhƒŠƒA‹@”\‚ւ̉e‹¿‚ɂ‚¢‚Ä•ñ‚ðs‚Á‚½BÅ‹ßA‘SƒQƒmƒ€‚ªŽ©—¥‘B‚·‚éHCV RNAƒŒƒvƒŠƒRƒ“Œn‚âHCVŠ´õŒn‚ªŠm—§‚³‚êA–«CŒ^ŠÌ‰Š‚É‚¨‚¯‚éŠà”­Ç‹@\‚̈ê‚‚Ƃµ‚ÄAŠà—}§ˆâ“`ŽqŽY•¨‚Å‚ ‚é”ñŽó—e‘ÌŒ^ƒ`ƒƒVƒ“ƒLƒi[ƒ[Syk‚Ƃ̊֌W‚ɂ‚¢‚Ä’²‚ׂ½‚Æ‚±‚ëASyk‚ªNS5A‚ɉµA‚»‚ÌŠˆ«‚ð—}§‚·‚邱‚Ƃ𖾂炩‚É‚µ‚½BHCV’`”’Ž¿‚Ì”­Œ»‚É‚æ‚èŠÌ×–EŠà‚ª”­Ç‚·‚郃JƒjƒYƒ€‚̈ê‚‚Ƃµ‚ÄAƒ`ƒƒVƒ“ƒLƒi[ƒ[‚ð‰î‚·‚éƒVƒOƒiƒ‹“`’B‹@\‚Ì”j’]‚ªl‚¦‚ç‚ê‚éi“Še’†jB‚³‚ç‚É–«CŒ^ŠÌ‰Š‚ɇ•¹‚·‚铜”A•a‚Ì”­ÇƒƒJƒjƒYƒ€‚ɂ‚¢‚ĉðÍ‚µAHCV‚ªGLUT2AGLUT1‚Ì×–E–Œ•\–ʂւ̔­Œ»—}§‚ð‰î‚µ‚ăOƒ‹ƒR[ƒXŽæ‚螂݂ð—}§‚·‚邱‚Æ‚ðŒ©o‚µ‚½i“Še’†jBŒö“IŒ¤‹†”ï‚Æ‚µ‚ÄC ‰ÈŠwŒ¤‹†”ï•â•‹àEŠî”ÕŒ¤‹†i‚bju‚bŒ^ŠÌ‰ŠƒEƒCƒ‹ƒX’`”’Ž¿‚É‚æ‚éŠÌ×–E‚Ì’`”’Ž¿ƒ`ƒƒVƒ“ƒŠƒ“Ž_‰»”½‰ž‚ւ̉e‹¿viŒ¤‹†‘ã•\ŽÒ@’è´’¼j‚ðŽó‚¯‚½B

 

œ  “ÁF“™

1. ‚í‚ê‚í‚ê‚ÍA]—ˆuŒq‚¬–ðv‚Æ‚µ‚Ä‘¨‚¦‚ç‚ê‚Ä‚¢‚½ƒAƒ_ƒvƒ^[’`”’Ž¿‚É‚æ‚éϋɓI‚È×–E‰ž“š‚ÌŽd‘g‚݂ɂ‚¢‚Ä–¾‚ç‚©‚É‚µ‚Ä‚«‚½B3BP2‚ªƒ}ƒXƒg×–E‚É”­Œ»‚µAIgE‚ð‰î‚·‚éƒAƒŒƒ‹ƒM[‰ž“š‚ð³‚ɧŒä‚·‚邱‚Æ‚ðŒ©o‚µ‚½B‚Ü‚½3BP2‚̃mƒbƒNƒAƒEƒgƒ}ƒEƒX‚Ì•\Œ»Œ^‚ª•ñ‚³‚ê‚邿‚è‚à‚©‚È‚è‘O‚ÉAsiRNA‚ð—p‚¢‚ÄƒŠƒ“ƒp‹…Šˆ«‰»ƒVƒOƒiƒ‹‚É‚¨‚¯‚é•K‘R“I‚È–ðŠ„‚ð–¾‚ç‚©‚É‚µ‚½B‚±‚ê‚ç‚̓Ƒn“I‚È•ñ‚Í2006”N‚ÉCellŽ‚âNature ImmunologyŽAAnnual Review of ImmunologyŽã‚ňø—p‚³‚êA‚í‚ê‚í‚ê‚ÌŒ¤‹†¬‰Ê‚ªƒAƒ_ƒvƒ^[’`”’Ž¿‚É‚æ‚é×–E‰ž“š‚̧Œä‹@\‚Ì—‰ð‚É‹­‚¢‰e‹¿‚ð—^‚¦‚±‚Æ‚ðŽ¦‚µ‚Ä‚¢‚éBŒ»ÝƒAƒ_ƒvƒ^[’`”’Ž¿3BP2‚ÌŒ¤‹†‚ł͢ŠE‚ÌÅæ’[‚ð‘–‚Á‚Ä‚¢‚邱‚Æ‚ðŽ©•‰‚µ‚Ä‚¢‚éB‚í‚ê‚í‚ê‚ÌŒ¤‹†‚ÍA3BP2‚̈â“`ŽqˆÙí‚É‚æ‚éƒqƒg‚̈â“`޾гƒPƒ‹ƒrƒYƒ€‚Ì”­ÇƒƒJƒjƒYƒ€‰ð–¾A‚³‚ç‚ɂ͊֘A‚·‚éŽ¾Š³‚ÌŽ¡—Ö@ŠJ”­‚ȂǗlX‚È”­“W«‚ð—L‚·‚邯l‚¦‚ç‚ê‚éB

‹¤“¯Œ¤‹†‚̬‰Ê‚Æ‚µ‚Ä•ñ‚µ‚½ƒ~ƒgƒRƒ“ƒhƒŠƒA‚̃†ƒrƒLƒ`ƒ“ƒŠƒK[ƒ[‚ɂ‚¢‚Ă̌¤‹†‚ÍA”ñí‚É‚‚¢…€‚ÌŽGނɔ­•\‚µ‚½iEMBO JOurnal, IF: 10.086jB

2.
–{”N‚Ì”­•\˜_•¶‚̂Ȃ©‚Å‚ÍHCVƒEƒCƒ‹ƒX’`”’Ž¿‚É‚æ‚éhŽå’`”’Ž¿‚Æ‚Ì‘ŠŒÝì—p‚Æ•aŒ´«A‚·‚Ȃ킿ŠÌ×–EŠà”­ÇƒƒJƒjƒYƒ€‚ւ̉e‹¿‚̉𖾂ª“Á•M‚³‚ê‚éB]—ˆAHCV‚ÌŒ¤‹†‚ł͎©—¥‚µ‚ăEƒCƒ‹ƒX—±Žq‚ª‘B‚Å‚«‚éƒVƒXƒeƒ€‚ª¢ŠE‚ÅŒ©‚‚©‚Á‚Ä‚¢‚È‚©‚Á‚½‚½‚ß‚ÉAHCV repliconƒVƒXƒeƒ€‚ª‘㊷ƒVƒXƒeƒ€‚Æ‚µ‚Ä—p‚¢‚ç‚ê‚Ä‚«‚½B‚±‚ê‚ÍHCVƒQƒmƒ€‚ðˆê•”‘€ì‚µ‚½RNA‚ð×–E‚É“±“ü‚·‚邯AƒQƒmƒ€‚ª•¡»‚³‚ê‚邪AƒEƒCƒ‹ƒX—±Žq‚ÍŽY¶‚³‚ê‚È‚¢ƒVƒXƒeƒ€‚Å‚ ‚éB‚±‚ÌŽd‘g‚Ý‚ÆAŠeƒEƒCƒ‹ƒX’`”’Ž¿‚ðŒÂ•ʂɔ­Œ»‚³‚¹‚é•û–@‚𕹗p‚·‚邱‚Ƃɂæ‚èA‚±‚ê‚܂Ŗ¾‚ç‚©‚É‚³‚ê‚Ä‚±‚È‚©‚Á‚½HCV‚Ì”ñ\‘¢’`”’Ž¿‚É‚æ‚éŠà—}§’`”’Ž¿p53‚Ì‹@”\‚ð—}§‚·‚éŒø‰Ê‚Æ•ªŽqƒƒJƒjƒYƒ€‚𖾂炩‚É‚µ‚½‚±‚Ƃ͓Á•M‚É’l‚·‚éB‚³‚ç‚É‚²‚­Å‹ßA‘S‚­V‚µ‚¢HCVŠ´õŽÀŒ±Œn‚ª“oꂵA‚í‚ê‚í‚ê‚à‚¢‚¿‘‚­‚»‚̃VƒXƒeƒ€‚𓱓ü‚µ‚ÄA‚±‚ê‚܂Œm‚ç‚ê‚邱‚Ƃ̂Ȃ©‚Á‚½’`”’Ž¿ƒ`ƒƒVƒ“ƒŠƒ“Ž_‰»”½‰ž‚ւ̉e‹¿‚ɂ‚¢‚͉»Šw“IŒ©’n‚©‚猟“¢‚ð‰Á‚¦‚Ä‚¢‚邱‚Æ‚à‘å‚«‚È“ÁF‚Å‚ ‚éBHCV‚Ì•aŒ´«”­Œ»‹@\‚ÉŠÖ‚·‚邱‚ê‚ç‚ÌŒ¤‹†¬‰Ê‚Í‚¢‚¸‚ê‚à‘n–ò‚ÌŠÏ“_‚©‚ç”­“W«‚ð—L‚·‚é‚à‚̂ƈʒu•t‚¯‚ç‚ê‚éB

 

œ  –{Šw‚Ì—”O‚Ƃ̊֌W

d“_“IŒ¤‹†•ª–ì‚̂ЂƂ‚ł ‚éA–Ɖu‚ÉŠÖ‚·‚邎Ÿ¶‘̃VƒXƒeƒ€‚Ì\’z‚âˆÛŽ‚É‚Â‚¢‚Ă̕ªŽqƒƒJƒjƒYƒ€‚̉ð͂ɂ‚¢‚ÄA‚í‚ê‚í‚ê‚ÌŽ‚¶‰»Šw‚ƃEƒCƒ‹ƒXŠw‚Æ‚¢‚¤ˆÙ‚È‚éƒoƒbƒNƒOƒ‰ƒEƒ“ƒh‚ð¶‚©‚µA‘¼‘åŠwEŒ¤‹†Š‚Ƃ̋¤“¯Œ¤‹†‚ð’Ê‚¶‚ÄA“–ŠY•ª–ì‚É‚¨‚¯‚颊E…€‚ÌŒ¤‹†¬‰Ê‚ð‹“‚°‚½‚Æl‚¦‚ç‚ê‚éB¡Œã‚Í«—ˆ‚ÌŒ¤‹†‚ð’S‚¤lވ笂ɂàϋɓI‚ÉŠÖ‚í‚Á‚Ä‚¢‚«‚½‚¢B

 

 

 

3D    Œ¤‹†ŽÀÑ

‹æ@@•ª

•Ò@@”

ƒCƒ“ƒpƒNƒgƒtƒ@ƒNƒ^[ (‚¤‚¿Œ´’˜‚Ì‚Ý)

2001`2006”N•ª

2006”N•ª

2001`2006”N•ª

2006”N•ª

˜a•¶Œ´’˜˜_•¶

0

0

\\\\\

\\\\\

‰p•¶˜_•¶

̧°½Äµ°»°

34

0

104.410 ( 104.410)

0.000 ( 0.000)

ºÚ½ÎßÝÃިݸ޵°»°

33

0

102.101 ( 102.101)

0.000 ( 0.000)

‚»‚Ì‘¼

7

7

26.396 ( 26.396)

26.396 ( 26.396)

‡Œv

41

7

130.806 ( 130.806)

26.396 ( 26.396)

 

 

 

iAj      ’˜‘E˜_•¶“™

(1)    ‰p•¶F˜_•¶“™

aDŒ´’˜˜_•¶iR¸—Lj

0622001

+M.Tanaka, +M.Nagano-Fujii, +L.Deng, +S.Ishido, K.Sada, +H.Hotta: Single-point mutations of hepatitis C virus NS3 that impair p53 interaction and anti-apoptotic activity of NS3. Biochem Biophys Res Commun, 340i3j, 792-799, 2006.02, #2.855

 

0622002

+L.Deng, +M.Nagano-Fujii, +M.Tanaka, +Y.Nomura-Takigawa, +M.Ikeda, +N.Kato, K.Sada, +H.Hotta: The NS3 protein of hepatitis C virus associates with the tumor suppressor p53 and inhibits its function in an NS3 sequence-dependent manner. J Gen Virol, 87i6j, 1703-1713, 2006.06, #3.110

 

0622003

+H.Hotta, +K.Nihei, +Y.Abe, +S.Kato, +D.P.Jiang, +M.Nagano-Fujii, K.Sada: Full-length sequence analysis of subacute sclerosing panencephalitis (SSPE) virus, a mutant of measles virus, isolated from brain tissues of a patient shortly after onset of SSPE. Microbiol Immunol, 50i7j, 525-534, 2006.07, #1.502

 

0622004

+Y.Nomura-Takigawa, +M.Nagano-Fujii, +L.Deng, +S.Kitazawa, +S.Ishido, K.Sada, +H.Hotta: The nonstructural protein 4A of hepatitis C virus accumulates on mitochondria and induces apoptotic cell death through a mitochondria-mediated pathway. J Gen Virol, 87i7j, 1935-1945, 2006.07, #3.110

 

0622005

+M.Otaki, K.Sada, +H.Kadoya, +M.Nagano-Fujii, +H.Hotta: Inhibition of measles virus and subacute sclerosing panencephalitis virus by RNA interference. Antiviral Res, 70i3j, 105-111, 2006.07, #2.878

 

0622006

+R.Yonashiro, +S.Ishido, +S.Kyo, +T.Fukuda, +E.Goto, +Y.Matsuki, +M.Ohmura-Hashimoto, K.Sada, +H.Hotta, +H.Yamamura, +R.Inatome, +S.Yanagi: A novel mitochondria ubiquitin ligase plays a critical role in mitochondrial dynamics. EMBO J, 25i15j, 3618-3626, 2006.08, #10.086

 

0622007

+K.Tsuji-Naito, T.Hatani, +T.Okada, +T.Tehara: Evidence for covalent lipoyl adduction with dopaquinone following tyrosinase-catalyzed oxidation. Biochem Biophys Res Commun, 343i1j, 15-20, 2006, #2.855

 

(2)    ˜a•¶F˜_•¶“™

bD‘à

(0522028)

’è@´’¼: ƒ}ƒXƒg×–EŠˆ«‰»ƒVƒOƒiƒ‹‚ð§Œä‚·‚镪Žq. Molecular Medicine, 42i10j, 1107-1112, 2005

 

(0522029)

’è@´’¼: ”ì–ž×–E‚É‚¨‚¯‚éFcepsilonƒŒƒZƒvƒ^[I‚©‚ç‚̃VƒOƒiƒ‹“`’BF3BP2‚ÆCbl-b‚É‚æ‚é”ì–ž×–EŠˆ«‰»§Œä. —Õ°–Ɖu, 44i1j, 63-70, 2005

 

 

 

iBj      Šw‰ï”­•\“™

(1)    ‘ÛŠw‰ï

aDˆê”Êu‰‰iƒ|ƒXƒ^[j

(0522030)

+Y.Nomura-Takigawa, +H.Hotta, +M.Nagano-Fujii, +L.Deng, +S.Kitazawa, +S.Ishido, K.Sada: The nonstructural protein 4A of hepatitis C virus accumulates on mitochondria and induces apoptotic cell death through the mitochondria-mediated pathway, 12th International Symposium on Hepatitis C Virus and Related Viruses, 2005, Montréal(Canada), Abstract, 121, 2005

 

(0522031)

+M.Nagano-Fujii, +S.Inubushi, +H.Mizuta, +M.Tanaka, +H.Yamamura, K.Sada, +K.Hotta: The nonstructural protein 5A of hepatitis C virus associates with and negatively regulates the enzymatic activity of non-receptor tyrosine kinase Syk in Huh-7 cells, 12th International Symposium on Hepatitis C Virus and Related Viruses, 2005, Montréal(Canada), Abstract, 132, 2005

 

0622008

+S.Inubushi, +M.Nagano-Fujii, +C.An, +K.Kitayama, +H.Yokozaki, +H.Yamamura, +M.Ikeda, +N.Kato, K.Sada, +H.Hotta: Hepatitis C virus NS5A protein associates with and negatively regulates a non-receptor protein-tyrosine kinase Syk in Huh-7 cells, The 20th IUBMB International Congress of Biochemistry and Molecular Biology, 2006.06, Kyoto(Japan), Abstract, 206, 2006

 

0622009

K.Takeuchi, T.Komatsu, +B.Gotoh: Blockage of PKR activation in Sendai virus infected cells: Involvement of the viral C gene, The 20th IUBMB International Congress of Biochemistry and Molecular Biology, 2006.06, ‹ž“sŽs

 

0622010

+A.El-Shamy, +M.Sasayama, +M.Nagano-Fujii, K.Sada, +S.R.Kim, +H.Hotta: A high degree of sequence variation of HCV NS5A and the presence of anti-NS5A antibodies in the pretreatment sera are associated with efficient viral clearance by combination therapy using pegylated interferon and ribavirin, 13th International Symposium on Hepatitis C Virus and Related Viruses, 2006.08, Sydney(Australia), Abstract, 63, 2006.08

 

0622011

K.Sada, +H.Yamamura, +H.Hotta: Regulation of IgE-mediated mast cell activation by 3BP2 and Cbl-b., International symposium of Kobe University 21st Century COE Program. on signal transduction, In memory of Prof. Yasutomi Nishizuka, 2006.12, Kobe(Japan), Abstract, 45, 2006

 

0622012

+S.Inubushi, +M.Nagano-Fujii, +K.Kitayama, +H.Yamamura, K.Sada, +H.Hotta: Kinase activity of the non-receptor tyrosine kinase Syk is down-regulated in Huh-7.5 cells harboring an HCV RNA subgenomic replicon, 13th International Symposium on Hepatitis C Virus and Related Viruses, 2006, Sydney(Australia), Abstract, 129, 2006

 

(2)    ‘“àŠw‰ïi‘S‘ƒŒƒxƒ‹j

aDƒVƒ“ƒ|ƒWƒXƒgEƒpƒlƒŠƒXƒg“™

0622013

+–x“c@”Ž, +’·–ì@ŠîŽq, ’è@´’¼: CŒ^ŠÌ‰ŠƒEƒCƒ‹ƒX”ñ\‘¢’`”’Ž¿NS3‚ÆNS4A‚Ì×–E•Ï«ì—p‚Æ×–E‚ª‚ñ‰»‚Ö‚ÌŠÖ—^, ‘æ10‰ñ“ú–{ŠÌ‘ŸŠw‰ï‘å‰ïE“ú–{ŠÌ‘ŸŠw‰ï, 2006.10, ŽD–y, u‰‰—vŽ|, A308, 2006

 

bDˆê”Êu‰‰iŒû‰‰j

(0522032)

+’·–ì@ŠîŽq, +Œ¢•š@ËŽq, +“c’†@Šî•¶, +ˆÀ@t‰p, +–쑺@—º‘¾, +X“c@‰Á“ÞŽq, ’è@´’¼, +–x“c@”Ž: CŒ^ŠÌ‰ŠƒEƒCƒ‹ƒXNS5A‚Í”ñŽó—e‘ÌŒ^ƒ`ƒƒVƒ“ƒLƒi[ƒ[Syk‚ɉµ‚»‚̃Lƒi[ƒ[Šˆ«‚𕉂ɧŒä‚·‚é, ‘æ53‰ñ“ú–{ƒEƒCƒ‹ƒXŠw‰ïŠwpW‰ïE“ú–{ƒEƒCƒ‹ƒXŠw‰ï, 2005, ‰¡•l, ´˜^W, 198, 2005

 

0622014

+’·–ì@ŠîŽq, +Ahmed El Shamy, +‹à@Žç—Ç, +ˆä–{@•×, +•w–Ø@Gˆê, +‹à@Œ[“ñ, +’JŒû@”üK, ’è@´’¼, +–x“c@”Ž: –«CŒ^ŠÌ‰Š‚ɑ΂·‚éƒyƒOƒCƒ“ƒ^[ƒtƒFƒƒ“/ƒŠƒoƒrƒŠƒ“•¹—p—Ö@‚Ì‘ŠúŽ¡—ÃŒø‰Ê‚ÆCŒ^ŠÌ‰ŠƒEƒCƒ‹ƒXNS5A‚ÌV3—̈æƒAƒ~ƒmŽ_”z—ñ‘½—l«‚Ì‘ŠŠÖ‚É‚Â‚¢‚Ä, ‘æ42‰ñ“ú–{ŠÌ‘ŸŠw‰ï‘‰ïE“ú–{ŠÌ‘ŸŠw‰ï, 2006.05, ‹ž“s, u‰‰—vŽ|, A116, 2006

 

0622015

+Œã“¡•q, ¬¼@Fs, ’|“à@Œ’Ži, +–kì‘P‹I: ƒqƒgƒƒ^ƒjƒ…[ƒ‚ƒEƒCƒ‹ƒX‚ƃCƒ“ƒ^[ƒtƒFƒƒ“’ïR”\, ‘æ54‰ñ“ú–{ƒEƒCƒ‹ƒXŠw‰ïŠwpW‰ï, 2006.11, –¼ŒÃ‰®Žs

 

cDˆê”Êu‰‰iƒ|ƒXƒ^[j

(0522033)

+‘å‘ë@“Žq, +’·–ì@ŠîŽq, +Šp–î@”Ž•Û, +‰Á“¡@½ˆê, +‘ëì@—L‹I, ’è@´’¼, +–x“c@”Ž: siRNA‚É‚æ‚éSSPEƒEƒCƒ‹ƒX‘B—}§–@ŠJ”­‚ÌŠî‘b“IŒŸ“¢, ‘æ53‰ñ“ú–{ƒEƒCƒ‹ƒXŠw‰ïŠwpW‰ïE“ú–{ƒEƒCƒ‹ƒXŠw‰ï, 2005, ‰¡•l, ´˜^W, 243, 2005

 

(0522034)

+Maria Inge Lusida, +’·–ì@ŠîŽq, +X“c@‰Á“ÞŽq, +ùŽR@”ü‹IŽq, ’è@´’¼, +–x“c@”Ž: ƒCƒ“ƒhƒlƒVƒA‚Ì‚aŒ^ŠÌ‰ŠƒEƒCƒ‹ƒX‚Ìgenotype‰ð͂ƃEƒCƒ‹ƒXi‰»‚ÌlŽ@, ‘æ53‰ñ“ú–{ƒEƒCƒ‹ƒXŠw‰ïŠwpW‰ïE“ú–{ƒEƒCƒ‹ƒXŠw‰ï, 2005, ‰¡•l, ´˜^W, 296, 2005

 

(0522035)

+‰Á“¡@½ˆê, +’·–ì@ŠîŽq, +‘å‘ë@“Žq, +î–{@^Ž¡, ’è@´’¼, +–x“c@”Ž: ˆŸ‹}«d‰»«‘S”]‰Š(SSPE)”­ÇŒã‘Šú‚É•ª—£‚µ‚½SSPEƒEƒCƒ‹ƒX‚̃Qƒmƒ€\‘¢‚ƃEƒCƒ‹ƒX«ó‚̉ðÍ, ‘æ53‰ñ“ú–{ƒEƒCƒ‹ƒXŠw‰ïŠwpW‰ïE“ú–{ƒEƒCƒ‹ƒXŠw‰ï, 2005, ‰¡•l, ´˜^W, 319, 2005

 

0622016

+‹à@Žç—Ç, +ˆä–{@•×, +’JŒû@”üK, +‹à@Œ[“ñ, +’·–ì@ŠîŽq, ’è@´’¼, +–x“c@”Ž: PEG-IFN+ƒŠƒoƒrƒŠƒ“•¹—p—Ö@‚ÌŒø‰Ê—\‘ª‚É‚¨‚¯‚é2f-5fƒIƒŠƒSƒAƒfƒjƒŒƒCƒg‡¬y‘f(2-5AS)‚̉ž“š«‚ÌŒŸ“¢, ‘æ42‰ñ“ú–{ŠÌ‘ŸŠw‰ï‘‰ïE“ú–{ŠÌ‘ŸŠw‰ï, 2006.05, ‹ž“s, u‰‰—vŽ|, A218, 2006

 

0622017

+‹à@Žç—Ç, +ˆä–{@•×, +–x“c@”Ž, +’JŒû@”üK, +‹à@Œ[“ñ, +’·–ì@ŠîŽq, ’è@´’¼: PEG-IFN+ƒŠƒoƒrƒŠƒ“•¹—p—Ö@‚ÌŽ¡—ÃŒø‰Ê—\‘ª‚É‚¨‚¯‚éƒEƒCƒ‹ƒXdynamics‚ÌŒŸ“¢, ‘æ42‰ñ“ú–{ŠÌ‘ŸŠw‰ï‘‰ïE“ú–{ŠÌ‘ŸŠw‰ï, 2006.05, ‹ž“s, u‰‰—vŽ|, A221, 2006

 

0622018

+’·–ì@ŠîŽq, +–x“c@”Ž, +Ahmed El Shamy, ’è@´’¼, +‹à@Žç—Ç, +ˆä–{@•×, +•w–Ø@Gˆê, +‹à@Œ[“ñ, +’JŒû@”üK: ƒyƒOƒCƒ“ƒ^[ƒtƒFƒƒ“^ƒŠƒoƒrƒŠƒ“•¹—p—Ö@–³Œø—á‚ÆHCV NS5A‚ÌV3—̈æƒAƒ~ƒmŽ_”z—ñ‘½—l«‹y‚ÑNS5AR‘̗̂L–³‚Æ‚Ì‘ŠŠÖ, ‘æ10‰ñ“ú–{ŠÌ‘ŸŠw‰ï‘å‰ïE“ú–{ŠÌ‘ŸŠw‰ï, 2006.10, ŽD–y, u‰‰—vŽ|, A400, 2006

 

0622019

+Ahmed El Shamy, +ùŽR@”ü‹IŽq, +’·–ì@ŠîŽq, +‹à@Žç—Ç, ’è@´’¼, +–x“c@”Ž: CŒ^ŠÌ‰ŠƒEƒCƒ‹ƒXNS5A‚̃Aƒ~ƒmŽ_”z—ñ‘½—l«‹y‚ÑŒŒ’†NS5AR‘̗̂L–³‚ƃyƒOƒCƒ“ƒ^[ƒtƒFƒƒ“^ƒŠƒoƒrƒŠƒ“•¹—p—Ö@‘ŠúŽ¡—ÃŒø‰Ê‚Æ‚Ì‘ŠŠÖ‚É‚Â‚¢‚Ä, ‘æ54‰ñ“ú–{ƒEƒCƒ‹ƒXŠw‰ïŠwpW‰ïE“ú–{ƒEƒCƒ‹ƒXŠw‰ï, 2006.11, –¼ŒÃ‰®, ´˜^W, 269, 2006

 

0622020

+Œ¢•š@ËŽq, +’·–ì@ŠîŽq, +–kŽR@Šì‹v”ü, ’è@´’¼, +–x“c@”Ž: CŒ^ŠÌ‰ŠƒEƒCƒ‹ƒXŠ´õ‚ª”ñŽó—e‘ÌŒ^ƒ`ƒƒVƒ“ƒLƒi[ƒ[Syk‚É‹y‚Ú‚·‰e‹¿, ‘æ54‰ñ“ú–{ƒEƒCƒ‹ƒXŠw‰ïŠwpW‰ïE“ú–{ƒEƒCƒ‹ƒXŠw‰ï, 2006.11, –¼ŒÃ‰®, ´˜^W, 259, 2006

 

0622021

¬¼@Fs, ’|“à@Œ’Ži, +Œã“¡•q: RSƒEƒCƒ‹ƒX‚̃Cƒ“ƒ^[ƒtƒFƒƒ“ƒAƒ“ƒ^ƒSƒjƒYƒ€, ‘æ54‰ñ“ú–{ƒEƒCƒ‹ƒXŠw‰ïŠwpW‰ï, 2006.11, –¼ŒÃ‰®Žs

 

0622022

’|“à@Œ’Ži, ¬¼@Fs, +Œã“¡•q: ƒZƒ“ƒ_ƒCƒEƒCƒ‹ƒX‚ÌIFN’ïR«F‘æŽO‚Ì‹@\, ‘æ54‰ñ“ú–{ƒEƒCƒ‹ƒXŠw‰ïŠwpW‰ï, 2006.11, –¼ŒÃ‰®Žs

 

(3)    ‘“àŠw‰ïi’nˆæƒŒƒxƒ‹j

aDˆê”Êu‰‰iŒû‰‰j

0622023

¬¼@Fs: ƒqƒgRSƒEƒCƒ‹ƒX‚̃Cƒ“ƒ^[ƒtƒFƒƒ“‘ÎR”\, ‘æ43‰ñ“ú–{׋ۊw‰ï’†•”Žx•”‘‰ï, 2006.10

 

bDˆê”Êu‰‰iƒ|ƒXƒ^[j

0622024

+Ahmed El Shamy, +ùŽR@”ü‹IŽq, +’·–ì@ŠîŽq, +‹à@Žç—Ç, ’è@´’¼, +–x“c@”Ž: –«CŒ^ŠÌ‰Š‚ɑ΂·‚éƒyƒOƒCƒ“ƒ^[ƒtƒFƒƒ“^ƒŠƒoƒrƒŠƒ“•¹—p—Ö@‘ŠúŽ¡—ÃŒø‰Ê‚ÆNS5A‚̃Aƒ~ƒmŽ_”z—ñ‘½—l«‚¨‚æ‚ÑŒŒ’†NS5AR‘̗̂L–³‚Æ‚Ì‘ŠŠÖ, ‘æ59‰ñ“ú–{׋ۊw‰ïŠÖ¼Žx•”‘‰ïE“ú–{׋ۊw‰ïŠÖ¼Žx•”, 2006.10, ‚’Î, —\eW, 45, 2006

 

 

 

iCj      ‚»‚Ì‘¼‹ÆÑ

·   ’è@´’¼: ƒtƒ‰ƒ“ƒX‘—§‰q¶ˆãŠwŒ¤‹†ŠEƒtƒ‰ƒ“ƒX“ï•aŒ¤‹†ŠŠO•”•]‰¿ˆõ, 2006.04`

 

 

 

4D    ƒOƒ‰ƒ“ƒgŽæ“¾@@

iAj      ‰ÈŒ¤”ïEŒ¤‹†•¬‹à“™

‹æ•ª

Œ¤‹†Ží–Ú

‰Û@‘è@–¼

‘ã•\ŽÒ–¼

•ª’SŽÒ–¼

Šú@ŠÔ

i”N“xj

‹à@Šz

i”z•ªŠzj

•¶•”‰ÈŠwȉȊw

Œ¤‹†”ï•â•‹à

Šî”ÕŒ¤‹†(C)ˆê”Ê

CŒ^ŠÌ‰ŠƒEƒCƒ‹ƒX’`”’Ž¿‚É‚æ‚éŠÌ×–E‚Ì’`”’Ž¿ƒ`ƒƒVƒ“ƒŠƒ“Ž_‰»”½‰ž‚ւ̉e‹¿

’è@´’¼

 

2006

2,700ç‰~

•¶•”‰ÈŠwȉȊw

Œ¤‹†”ï•â•‹à

Šî”ÕŒ¤‹†(C)ˆê”Ê

ƒqƒgƒƒ^ƒjƒ…[ƒ‚ƒEƒCƒ‹ƒX‚Ì•aŒ´«‚ƃCƒ“ƒ^[ƒtƒFƒƒ“ƒAƒ“ƒ^ƒSƒjƒYƒ€

Œã“¡@•q

 

2006

1,800ç‰~

Šw“à‹£‘ˆ“IŽ‘‹à

Šw’·Ù—ÊŒo”ïEŠî‘b“IE–G‰è“IŒ¤‹†

–ƉuŽhŒƒƒIƒŠƒSDNA palGACGA0901‚̃AƒŒƒ‹ƒM[EƒEƒBƒ‹ƒXŠ´õŽ¡—Âւ̉ž—p

*ˆÉ•Û@ŸŽq

’|“àŒ’Ži

2006

600ç‰~

Šw“à‹£‘ˆ“IŽ‘‹à

‹£‘ˆ“I”z•ªŒo”ïEŒ¤‹†

Œ`Ž¿×–E—lŽ÷ó×–E‚ÌŠˆ«‰»‚Æ‚»‚̧Œä‹@\‚̉ðÍ

*ˆÉ•Û@ŸŽq

’|“à@Œ’Ži, ¬¼@Fs

2006

500ç‰~

 

 

 

iBj      §ŠwŠñ•‹à

Žó“üŒ”

1@Œ

Žó“ü‹àŠz

91,206@‰~

 

 

 

 

5D    ŽY‹ÆEŽÐ‰ï‚Ö‚ÌvŒ£

iAj      ‘E’nˆæ“™‚Ö‚ÌvŒ£

(1)    R‹c‰ïEˆÏˆõ‰ïEŒö‰v–@lE‰ïŽÐ“™‚Ö‚ÌŽQ‰Áó‹µ

‹æ•ª

‹@ŠÖEˆÏˆõ‰ï‚Ì–¼Ì“™

–ðE

Ž–¼

ŠúŠÔ

’n•ûީޡ‘Ì

•ŸˆäŒ§, •ŸˆäŒ§Œ‹ŠjEŠ´õÇ—\–h‘ÎôˆÏˆõ‰ï

ˆÏˆõ

–Ø‘º@‹g‰„

2003.02`

’n•ûީޡ‘Ì

•ŸˆäŒ§‰q¶ŠÂ‹«ƒZƒ“ƒ^[Œ¤‹†‰Û‘è•]‰¿ˆÏˆõ‰ï

ˆÏˆõ

–Ø‘º@‹g‰„

2003.08`

’n•ûީޡ‘Ì

•ŸˆäŒ§‰q¶ŠÂ‹«¾ÝÀ°, Œ¤‹†‰Û‘è•]‰¿ˆÏˆõ‰ï

ˆÏˆõ

–Ø‘º@‹g‰„

2005.08`

‚»‚Ì‘¼

•ŸˆäŒ§, •ŸˆäŒ§Œ‹ŠjEŠ´õÇ—\–h‘ÎôˆÏˆõ‰ï

ˆÏˆõ

–Ø‘º@‹g‰„

2005.01`

 

 

 

(2)    ŽÐ‰ïl“™‚Ö‚ÌvŒ£‹y‚ÑŠwZ“™‚Ƃ̘AŒgE‹¦—͂ɂæ‚銈“®

‹æ•ª

Šˆ“®–¼EŠˆ“®“à—e

ŽåÃŽÒE‘ÎÛŽÒ“™

Ž–¼

‚»‚Ì‘¼

SPP, ”÷¶•¨Šw‚ւ̵‘Ò

‚Z¶

’è@´’¼

 

 

 

iBj      ‚»‚Ì‘¼‹ÆÑ

·   –Ø‘º@‹g‰„: Clinical Infectious Diseases, R¸ˆÏˆõ, 2005`